NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
1 year
Value
£417M
Sector
HEALTH
Published
23 Aug 2024
Delivery
01 Aug 2024 to 31 Jul 2025
Deadline
10 Apr 2024 12:00

Concepts

Location

Geochart for 1 buyers and 9 suppliers

1 buyer

9 suppliers

Description

roject title: CM/PHS/24/5707 NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 Period of framework: 1 August 2024 to 31 July 2025. with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Award Detail

1 Bayer (Green Park Reading)
  • Value: £416,830,570
2 Teva (None)
  • Value: £416,830,570
3 Roche Products (None)
  • Value: £416,830,570
4 Thornton & Ross (Huddersfield)
  • Value: £416,830,570
5 Abbvie (Maidenhead)
  • Value: £416,830,570
6 Biogen (Maidenhead)
  • Value: £416,830,570
7 Novartis Pharmaceuticals (London)
  • Value: £416,830,570
8 Alimera Sciences (Aldershot)
  • Value: £416,830,570
9 Orion Pharma (Abbey Gardens)
  • Value: £416,830,570

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

CM_PHS_24_5707_01_ROC CM_PHS_24_5707_01_ROC.pdf CM_PHS_24_5707_01_ABV CM_PHS_24_5707_01_ABV.pdf CM_PHS_24_5707_01_BIG CM_PHS_24_5707_01_BIG.pdf CM_PHS_24_5707_01_ALS CM_PHS_24_5707_01_ALS.pdf CM_PHS_24_5707_01_NVS CM_PHS_24_5707_01_NVS.pdf CM_PHS_24_5707_01_TVA CM_PHS_24_5707_01_TVA.pdf CM_PHS_24_5707_01_BAY CM_PHS_24_5707_01_BAY.pdf CM_PHS_24_5707_01_ORI CM_PHS_24_5707_01_ORI.pdf CM_PHS_24_5707_01_THR CM_PHS_24_5707_01_THR.pdf Document No. 03 - Framework Agreement and Terms and Conditions CM_PHS_24_5707 Document No. 03 - Framework Agreement and Terms and Conditions CM_PHS_24_5707.docx

Reference

Domains